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The constituent paired helical filaments (PHFs) in neurofibrillary tangles are
insoluble intracellular deposits central to the development of Alzheimer’s dis-
ease (AD) and other tauopathies. Full-length tau requires the addition of
anionic cofactors such as heparin to enhance assembly. We have shown that a
fragment from the proteolytically stable core of the PHF, tau 297-391 known
as ‘dGAE’, spontaneously forms cross-b-containing PHFs and straight fila-
ments under physiological conditions. Here, we have analysed and compared
the structures of the filaments formed by dGAE in vitro with those deposited
in the brains of individuals diagnosed with AD. We show that dGAE forms
PHFs that share a macromolecular structure similar to those found in brain
tissue. Thus, dGAEs may serve as a model system for studying core domain
assembly and for screening for inhibitors of tau aggregation.
Keywords: Alzheimer’s disease; neurofibrillary tangles; paired helical
filaments; tau
The pathology of Alzheimer’s disease (AD) is charac-
terised by the accumulation of amyloid-b protein in
senile plaques and tau in neurofibrillary tangles
(NFTs). This is associated with the neurodegenerative
features of the disease which includes oxidative stress,
inflammation and compromised axonal transport,
eventually resulting in neuronal cell death [1]. Tau pro-
tein is a product of the MAPT gene, and alternative
mRNA splicing generates six different isoforms of tau
varying in their length. The C terminus contains three
or four imperfect tandem repeats of a 31 or 32 amino
acid sequence [2–4]. Tau is a natively unfolded protein
which plays an important role in microtubule assembly
and stabilisation, vital for effective axonal transport
and signal transduction [5]. More recently, it has been
identified in nucleolar functions where it has been seen
to associate with nucleic acids [5].
In AD and other tauopathies, tau is deposited as
paired helical filaments (PHFs) and straight filaments
(SFs) in NFTs in cell bodies of neurons. The filaments
share a cross-b structure with amyloid fibrils [6], and
recent cryo-electron microscopy (cryo-EM) studies
Abbreviations
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have revealed atomic details of filaments isolated from
brain tissues of patients with AD [7], Pick’s disease [8]
and chronic traumatic encephalopathy [9]. PHFs and
SFs from AD are formed by two protofilaments con-
taining parallel in-register b-sheet structures. The
ordered structure resolved by cryo-EM (residues 306-
378) consists of several b-strands connected by b-bends
and a b-helix conformation to form a single layer of
the cross-b structure. The specific conformations of the
ordered domains of the filaments formed in the three
conditions differ, but all encompass approximately
residues 304-380 of the 4-repeat isoform or homolo-
gous residues of the 3-repeat isoform. All share a simi-
lar consensus conformation comprising a hairpin
structure, with different locations of poorly resolved
cofactors and different modes of association between
each protofilament. The ordered domains that have
been resolved by cryo-EM are all somewhat shorter
than the fragment originally isolated from proteolyti-
cally stable PHF core preparations (residues 296-391)
[10].
Full-length and fragments of tau have been studied
extensively to ascertain how they form filaments. How-
ever, often these are made with the anionic cofactor
heparin [11–13] RNA [14] or fatty acids [15], which
have been thought to be necessary to initiate assembly.
Recently, it has been found that the filaments prepared
using anionic cofactors are structurally heterogeneous
and distinct from those found in any of the diseases
studied to date [16,17]. Therefore, the field is in need
of a tractable and relevant form of tau for studying
self-assembly and pathology, and potentially develop-
ing therapeutic approaches targeting pathological
aggregation of tau protein.
dGAE is a truncated form of tau protein comprising
95 amino acids that correspond to residues 297-391 and
encompasses repeat regions 3 and 4 of the 4-repeat iso-
form. It corresponds to one of the species isolated from
proteolytically stable AD PHF preparations [10]. A
fragment of tau ending at residue 391 has been identi-
fied in amorphous deposits in brain tissue sections [18]
and within fuzzy-PHFs that retain N- and C-terminal
domains of tau isolated from AD brain [19]. The dGAE
peptide has been suggested to represent an important
stable core region of full-length tau [19–23] and con-
tains the ordered sequences that have been resolved by
cryo-EM in AD [7]. We have previously shown that
dGAE can self-assemble into filaments without the
addition of anionic cofactors and that these filaments
not only share characteristics with amyloid, but also
resemble the PHFs found in AD brains [24]. The self-
assembled filaments were mainly PHFs with a minority
(approximately 10%) of SFs (see Ref. [24]). Here, we
have performed an in-depth study to compare the
macromolecular structure of the PHFs in NFTs in the
brain of an AD patient with the PHFs formed by
dGAE. Using transmission electron microscopy (TEM)
and atomic force microscopy (AFM), we show that
these dGAE PHFs are comparable to PHFs found in
AD brains at a macromolecular level.
Materials and methods
Brain tissue block preparation
Alzheimer’s disease brain tissue from middle frontal
gyrus was obtained from London Neurodegenerative Dis-
eases Brain Bank. Removal of the tissue was carried out
according to Local Ethics Committee guidelines and
informed consent for brain donation was obtained from the
next of kin. The tissue was stored at 80 °C in a designated
locked HTA freezer. Frozen tissue was transported on dry
ice in order to preserve its structure and integrity to a Class
II Type A2 biological safety cabinet. A sample of around 1
mm3 was excised using a scalpel blade (#22), placed immedi-
ately into a 1.5 mL Eppendorf tube containing a fixative
solution (4% paraformaldehyde, 0.1% glutaraldehyde in
PBS 19) and left at 4 °C overnight. The following day, the
fixative solution was washed out using PBS five times over a
period of 4 h. During the washes, samples were rotated at
4 °C. This washing was necessary to remove residual alde-
hyde which can interfere with labelling in subsequent steps.
Following the buffer rinse, samples were dehydrated using
solutions of increasing EtOH concentrations (30%, 50%,
75%, 90%, 39 100%, each for 20 min). Following the 100%
EtOH step, the sample was prepared for embedding in resin
(UNICRYL; BBI Solutions, Crumlin, UK) by primary incu-
bation in a 100% EtOH : resin (2 : 1) solution for 2 h fol-
lowed by a secondary incubation using a 1 : 2 ratio (30 min
for both incubation steps) before moving into complete resin
overnight at 4 °C. The following day the resin was replaced
with fresh resin, and the sample was moved into a BEEM
capsule (Agar Scientific, Essex, UK). Resin polymerisation
was performed under UV light for 3–4 days at 4 °C until the
resin was fully polymerised. The finished block was then
removed from the BEEM capsule and prepared for ultrathin
sectioning.
Ultrathin sectioning
Polymerised tissue blocks were mounted on the sample
holder of a Leica EM UC7 ultramicrotome. The tissue was
located in the block and an area of roughly trapezoidal
shape was cut using a razor blade (Astra superior platinum
double edge razor blade). In order to remove the superficial
layer of resin present on the tissue, a glass knife was used
initially. Once the tissue was exposed, ultrathin sections of
60 nm were cut using a diamond knife (Ultra Diamond
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Knife – Wet 45° 2.5 mm). Sections were collected on hexag-
onal 300-mesh Nickel grids (3.05 mm; Agar Scientific)
ready for immunogold labelling.
Immunogold labelling of tissue sections for TEM
An established methodology was followed for the immuno-
gold labelling [25]. PBS+, a modified PBS at pH 8.2 contain-
ing 1% BSA, 500 lLL1 Tween-20, 10 mM Na EDTA and
0.2 gL1 NaN3, was used for all the following procedures,
including dilutions of antibodies and secondary gold probes.
PBS + buffer was used for immunoreagent dilutions and for
rinsing. The grids were incubated first with normal goat
serum (20 lL; 1 : 10 dilution) for 30 min at room tempera-
ture in order to block the binding of nonspecific secondary
antibodies. Grids were then labelled with either T22 rabbit
polyclonal anti-tau antibody (ABN454; Merck Millipore,
Darmstadt, Germany) (1 : 1000 dilution), total tau rabbit
polyclonal anti-tau antibody (SAB4501821; Sigma-Aldrich
Company Ltd., Gillingham, UK) (1 : 1000 dilution) or
mAb 423 (1 : 20 dilution) [19,26] and incubated overnight
at 4 °C. The sections were rinsed 3 9 2 min with
PBS + buffer. The sections were then immunolabelled either
with goat anti-rabbit IgG with 10-nm gold particles
(GaR10) or, for mAb 423, with goat anti-mouse IgG with
10-nm gold particles (GaM10) as secondary probes (all
1 : 10 dilution), for 1 h at room temperature. After 3 9 10-
min PBS + buffer and 4 9 5-min distilled water rinses, the
grids were then poststained with 0.22-lm-filtered 0.5% (w/
v) aqueous uranyl acetate (positive stain) for 1 h. The grids
were then rinsed a further 5 9 2 min with water before
allowing to dry. TEM projection images were collected
using a JEOL JEM1400-Plus Transmission Electron Micro-
scope operated at 120 kV equipped with a Gatan OneView
camera (4k 9 4k). Images were recorded at 25 fps with drift
correction using GMS3. Only filaments with a twisted
appearance were selected for analysis.
Assembly of truncated dGAE tau fibrils
dGAE (300 lM) was incubated in phosphate buffer
(10 mM, pH 7.4) containing 10 mM DTT at 37 °C with
agitation at 400 oscillations per minute (Eppendorf
Thermomixer C, Eppendorf, Germany) for 48 h.
Negative stain TEM
Electron microscopy grids were prepared by placing a sam-
ple of dGAE fibrils (4 lL) onto formvar/carbon-coated
400-mesh copper grids (Agar Scientific). Excess sample was
blotted with filter paper and then washed with 0.22-lm-
filtered milli-Q water (4 lL). Uranyl acetate (2% w/v;
Fig. 1. (A) NFTs of tau from AD brain section immunogold labelled with anti-tau antibody T22 and total tau as labelled in the images. (B) PHFs
formed in vitro from dGAE. Apparent diameter (mean  SE) for narrow (Red arrow) and wide (Green arrow) sections of the filaments was
9.47  0.86 nm and 17.42  0.72 nm, respectively. The crossover repeat distance (blue bracket) for all filaments was 72.50  0.94 nm.
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4 lL) was added to the grid and left for 1 min before blot-
ting. The grid was then allowed to air-dry. TEM projection
images were collected using a JEOL JEM1400-Plus Trans-
mission Electron Microscope operated at 120 kV equipped
with a Gatan OneView camera (4k 9 4k). Images were
recorded at 25 fps with drift correction using GMS3. Only
filaments with a twisted appearance were selected for
analysis.
Immunogold labelling of dGAE filaments for TEM
Briefly, the immunogold labelling was performed by placing
4 lL of a dGAE filament preparation for 1 min on Form-
var/carbon-coated 400-mesh copper TEM support grids
(Agar Scientific), and then the excess was removed using fil-
ter paper. For blocking, grids were incubated with normal
goat serum (1 : 10 dilution) for 30 min at room tempera-
ture and then incubated with mAb 423 (1 : 20 dilution) for
2 h at room temperature. (mAb 423 was raised against
PHFs from AD brains and detects tau protein C-terminally
truncated at Glu-391 as reported in [19,26]). Grids were
washed three times with PBS+ for 2 min each and then
incubated with GaM10 secondary antibody (1 : 10 dilution)
for 1 h at room temperature. The grids were washed five
times with PBS+ for 2 min each followed by five washes
with distilled water (0.22-lm-filtered) for 2 min each. The
filaments were negatively stained with 2 % (w/v) uranyl
acetate (0.22 lm filtered) for 1 min. TEM projection
images were collected using a JEOL JEM1400-Plus Trans-
mission Electron Microscope operated at 100 kV equipped
with a Gatan OneView camera (4k 9 4k). Images were
recorded at 25 fps with drift correction using GMS3.
Atomic force microscopy
The dGAE fibril samples were prepared for AFM by
depositing 20 lL of sample on freshly cleaved highly ori-
ented pyrolytic graphite for 30 min followed by a 200-lL
wash with sterile filtered Milli-Q and drying of the surface
with nitrogen gas. The samples were imaged on a Bruker
Multimode 8 scanning probe microscope with a Nanoscope
V controller, using the ScanAsyst peak-force tapping imag-
ing mode. Bruker ScanAsyst-Air probes (nominal spring
constant of 0.4 Nm1 and nominal tip radius of 2 nm)
were used to scan 5 lm 9 5 lm areas of the surface at a
resolution of 1024 9 1024 pixels. The images were flattened
using Bruker Nanoscope Analysis software to remove tilt
and bow. The images were further processed in Matlab and
43 individual fibrils were traced and digitally straightened,
which allowed the measurement of peak and through
heights from the fibril centre line height profile and the
repeat periodicity. Fibril periodicity was determined using
the highest frequency peak from the Fourier transform of
the fibril centre line height profile. Only filaments with a
twisted appearance were selected for analysis.
Results
Negatively stained brain sections from an individual
diagnosed with AD were examined using TEM in
order to visualise the morphology of the filaments
in situ (in tissue without further processing or extrac-
tion) (Fig. 1A). dGAE was incubated with agitation
under reducing conditions for 48 h before examination
by TEM. The conditions for assembly have been opti-
mised to provide a consistent and even distribution of
PHF (with some SFs, approximately 10%) [24]. The
diameters and periodicity of the PHFs were measured
(Fig. 1B) and those formed in vivo and in vitro were
compared. Results revealed no significant variation
(P > 0.05) within different repeats of dGAE filament
preparations and no significant difference between the
dGAE and Alzheimer’s PHFs for wide, narrow and
crossover repeat measurements (Fig. 2).
dGAE filaments prepared in the same way as for
TEM were allowed to dry on freshly cleaved highly
oriented pyrolytic graphite and subsequent AFM
imaging revealed that the filaments formed by dGAE
have a left-handed twist (Fig. 3), the same handedness
as reported for AD PHFs [27]. Periodicity measure-
ments were indistinguishable from those obtained
using TEM, with in vivo and in vitro filaments, having
the same average periodicity of 72.7  1.6 nm
(Fig. 3B,C). The average filament centre height mea-
surements for these filaments reveal an average of
Fig. 2. Comparison of twisted dGAE filaments and PHFs from AD
brain tissue. Data were analysed using one-way ANOVA with
multiple comparisons and Sidak’s multiple comparisons test.
Eighty-two images were analysed for dGAE using five grids. Forty-
three images were analysed for AD PHFs using three grids from
one case. Narrow diameter comparison – mean diff. 0.03291 nm,
95% Cl of diff. 2.047 to 2.113 nm. Not significant (number of
measurements – dGAE: 95, AD: 17). Wide diameter comparison –
mean diff. 0.2626 nm, 95% Cl of diff. 1.763 to 1.711 nm. Not
significant (number of measurements – dGAE: 101, AD: 26).
Crossover repeat comparison – mean diff. 1.631 nm, 95% Cl of
diff. 0.6283 to 3.890 nm. Not significant (number of
measurements – dGAE: 66, AD: 15).
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11.7  0.2 nm for the peaks and 5.5  0.1 nm for the
troughs (Fig. 3B). The AFM height measurements are
marginally smaller than the apparent diameters mea-
sured from negative stain TEM. This would be
expected, since AFM height measurements are likely
underestimates of filament width due to compressing
effects from the AFM tip, while negative stain TEM
diameter measurements are likely overestimates of fila-
ment width arising from the apparent widening effect
of the negative stain envelope. However, the ratio
between AFM peak and trough heights of the dGAE
filaments is 2.1  0.3 nm, consistent with the ratio
between thick and thin filament regions of
1.8  0.4 nm from TEM images for dGAE filaments.
Therefore, all of the imaging data taken together
demonstrate that truncated tau forms filaments that
share macromolecular characteristics with PHFs found
in vivo.
To further compare the structural characteristics of
filaments formed by dGAE with those found in brain
tissue, we performed immunogold labelling using an
antibody which was raised against proteolytically
stable PHF preparations from AD brain tissues and
which recognises tau C-terminally truncated at Glu-
391 [19,26]. There was significant antibody labelling of
dGAE filaments (Fig. 4A) and immunogold labelling
was also observed in AD brain tissue sections
(Fig. 4B). This suggests that the regions of tau accessi-
ble to this antibody are present in both the dGAE
filaments formed in vitro and those found in situ.
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Fig. 3. AFM images of filaments made from dGAE under identical conditions as for TEM. (A) A 5 9 5 lm AFM image of dGAE filaments
with inset representing a cropped 49 magnified view. (B) Image of a typical traced and digitally straightened fibril (arrow in A) with the
height profile of along the centre of the fibril. (C) The Fourier transformed height profile showing peak representing the frequency of the
repeating pattern due to fibril twist, with insert representing the periodicity (1/frequency) of the twist. Measurements (mean  SE) from
n = 43 filaments are: periodicity, 72.7  1.6 nm; peak height, 11.7  0.2 nm; and trough height, 5.5  0.1 nm.
Fig. 4. Immunogold labelling TEM with mAb 423 of (A) PHFs formed in vitro from dGAE and (B) NFTs of tau from AD brain section.
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Discussion
In this study, we report that filaments formed from
the truncated tau (297-391) closely resemble PHFs
found in AD brains at the macromolecular level. Our
work reveals that, from negative stain images, the
in vitro filaments share similar characteristics with
those observed in AD brain, including width and peri-
odicity. We also reveal that they share similar epitopes
exposed on the surface of the filaments.
The relatively low resolution of these results pre-
cludes conclusions being drawn regarding the precise
molecular interactions within the core structure.
Indeed, filaments deposited in chronic traumatic
encephalopathy share similar morphology with those
from AD brains, whereas cryo-EM has revealed sub-
tle differences at the molecular level [9]. Work is
ongoing to characterise the molecular details of the
PHFs formed from dGAE, but only cryo-EM or
ssNMR will be able to provide definitive proof
regarding the comparison between the synthetic core
tau fragment filaments and PHFs formed in AD
brain and other conditions. It is not known as yet
whether the subtle ultrastructural differences between
morphologically similar filaments, forming from the
same or homologous underlying tau units in different
disease settings, are critical either for understanding
the molecular mechanism of assembly of the core tau
unit or in the development of novel therapeutic
approaches.
Here, the preparation of PHFs from truncated tau
was achieved without the addition of heparin. This
work also reveals that phosphorylation of tau is not
required for the formation of PHFs in vitro. Here, we
show that a tau fragment can form filaments sponta-
neously which are similar at the macromolecular level
to those deposited in AD brain tissue, and this may
provide a tractable model system for understanding
the molecular mechanism of assembly of the core
domain and for screening inhibitors.
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